| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 John D. Dingell Veterans Affairs Medical Center and Department of Medicine, Wayne State University and Karmanos Cancer Institute, Detroit, Michigan; 2 Burnham Institute, La Jolla, California; 3 Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, Oregon; 4 Department of Medicine and Pharmacology, The University of Kansas Medical Center, Kansas City, Kansas; and 5 Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas
Requests for reprints: Joseph A. Fontana, John D. Dingell Veterans Affairs Medical Center, Oncology 11M-HO, 4646 John R. Street, Detroit, MI 48201. Phone: 313-576-3659; Fax: 313-576-1122; E-mail: Joseph.Fontana{at}va.gov.
6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid (CD437/AHPN) and 4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC/MM002) are inducers of apoptosis of malignant cells both in vitro and in vivo. Numerous mechanisms have been proposed for how these compounds exert this effect. This report shows that AHPN/3-Cl-AHPC binds specifically to the orphan nuclear receptor small heterodimer partner (SHP; NR0B2), and this binding promotes interaction of the receptor with a corepressor complex that minimally contains Sin3A, N-CoR, histone deacetylase 4, and HSP90. Formation of the SHP-Sin3A complex is essential for the ability of AHPN and 3-Cl-AHPC to induce apoptosis, as both knockout SHP and knockdown of Sin3A compromise the proapoptotic activity of these compounds but not other apoptosis inducers. These results suggest that AHPN/3-Cl-AHPC and their analogues are SHP ligands and their induction of apoptosis is mediated by their binding to the SHP receptor. [Cancer Res 2007;67(1):318–25]
This article has been cited by other articles:
|
|
 |
|
  L. Farhana, M. I. Dawson, L. Xu, and J. A. Fontana SHP and Sin3A expression are essential for adamantyl-substituted retinoid-related molecule-mediated nuclear factor-{kappa}B activation, c-Fos/c-Jun expression, and cellular apoptosis Mol. Cancer Ther., June 1, 2009; 8(6): 1625 - 1635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R.M. Maran, A. Thomas, M. Roth, Z. Sheng, N. Esterly, D. Pinson, X. Gao, Y. Zhang, V. Ganapathy, F. J. Gonzalez, et al. Farnesoid X Receptor Deficiency in Mice Leads to Increased Intestinal Epithelial Cell Proliferation and Tumor Development J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 469 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Eloranta and G. A. Kullak-Ublick The Role of FXR in Disorders of Bile Acid Homeostasis Physiology, October 1, 2008; 23(5): 286 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Valli, G. Paroni, A. M. Di Francesco, R. Riccardi, M. Tavecchio, E. Erba, A. Boldetti, M. Gianni', M. Fratelli, C. Pisano, et al. Atypical retinoids ST1926 and CD437 are S-phase-specific agents causing DNA double-strand breaks: significance for the cytotoxic and antiproliferative activity Mol. Cancer Ther., September 1, 2008; 7(9): 2941 - 2954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sanyal, A. Bavner, A. Haroniti, L.-M. Nilsson, T. Lundasen, S. Rehnmark, M. R. Witt, C. Einarsson, I. Talianidis, J.-a. Gustafsson, et al. Involvement of corepressor complex subunit GPS2 in transcriptional pathways governing human bile acid biosynthesis PNAS, October 2, 2007; 104(40): 15665 - 15670. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
